An official with German pharmaceutical giant Bayer said during a conference call recently that the company intends to put substantial resources into getting new drugs out on the market.
During a recent conference call with J.P. Morgan Global, Jörg Reinhardt, the CEO of Bayer’s Healthcare Division, said a productivity and efficiency effort at the corporation is expected to produce an estimated $430 million in annual savings, “significant parts” of which will go toward development and launches of products.
“…We could already this ...
continue reading...